Revenues (Tables)
|
12 Months Ended |
Jan. 01, 2021 |
Revenue from Contract with Customer [Abstract] |
|
Schedule of Disaggregation of Revenue |
Revenues consisted of the following (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Year Ended December 31, | | | | | | 2020 | | 2019 | | 2018 | Product revenues: | | | | | | | | | | Gross product revenues | | | | | $ | 962,591 | | | $ | 957,621 | | | $ | 738,529 | | Discounts and allowances | | | | | (221,041) | | | (197,671) | | | (119,250) | | Net product revenues | | | | | 741,550 | | | 759,950 | | | 619,279 | | Collaboration revenues: | | | | | | | | | | License revenues | | | | | 167,295 | | | 165,914 | | | 200,272 | | Collaboration services revenues | | | | | 78,693 | | | 41,911 | | | 34,275 | | | | | | | | | | | | Total collaboration revenues | | | | | 245,988 | | | 207,825 | | | 234,547 | | Total revenues | | | | | $ | 987,538 | | | $ | 967,775 | | | $ | 853,826 | |
Net product revenues by product were as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Year Ended December 31, | | | | | | 2020 | | 2019 | | 2018 | CABOMETYX | | | | | $ | 718,687 | | | $ | 733,421 | | | $ | 599,946 | | COMETRIQ | | | | | 22,863 | | | 26,529 | | | 19,333 | | Net product revenues | | | | | $ | 741,550 | | | $ | 759,950 | | | $ | 619,279 | |
|
Schedule of Concentration Risks |
As of December 31, 2020 and 2019, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: | | | | | | | | | | | | | December 31, | | 2020 | | 2019 | Collaboration partners | | | | Ipsen | 23 | % | | 38 | % | Takeda | 10 | % | | 2 | % | Product revenue customers | | | | Affiliates of McKesson Corporation | 12 | % | | 14 | % | Affiliates of CVS Health Corporation | 11 | % | | 10 | % | Affiliates of AmerisourceBergen Corporation | 11 | % | | 11 | % | Affiliates of Optum Specialty Pharmacy | 8 | % | | 10 | % |
The percentage of total revenues by customer who individually accounted for 10% or more of our total revenues were as follows: | | | | | | | | | | | | | | | | | | | Year Ended December 31, | | 2020 | | 2019 | | 2018 | Ipsen | 15 | % | | 16 | % | | 21 | % | Affiliates of CVS Health Corporation | 14 | % | | 15 | % | | 13 | % | Affiliates of McKesson Corporation | 12 | % | | 12 | % | | 12 | % | Affiliates of Optum Specialty Pharmacy | 11 | % | | 13 | % | | 14 | % | Affiliates of AmerisourceBergen Corporation | 11 | % | | 11 | % | | 9 | % |
|
Revenues Disaggregated by Geographic Region |
Total revenues by geographic region were as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Year Ended December 31, | | | | | | 2020 | | 2019 | | 2018 | U.S. | | | | | $ | 752,890 | | | $ | 770,244 | | | $ | 632,927 | | Europe | | | | | 151,631 | | | 152,771 | | | 182,879 | | Japan | | | | | 83,017 | | | 44,760 | | | 38,020 | | Total revenues | | | | | $ | 987,538 | | | $ | 967,775 | | | $ | 853,826 | |
|
Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances |
The activities and ending allowance balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Chargebacks, Discounts for Prompt Payment and Other | | Other Customer Credits/Fees and Co-pay Assistance | | Rebates | | Total | Balance at December 31, 2018 | $ | 2,322 | | | $ | 3,038 | | | $ | 11,916 | | | $ | 17,276 | | Provision related to sales made in: | | | | | | | | Current period | 129,936 | | | 15,605 | | | 48,250 | | | 193,791 | | Prior periods | 3,989 | | | (111) | | | 2 | | | 3,880 | | Payments and customer credits issued | (128,733) | | | (15,035) | | | (44,946) | | | (188,714) | | Balance at December 31, 2019 | 7,514 | | | 3,497 | | | 15,222 | | | 26,233 | | Provision related to sales made in: | | | | | | | | Current period | 146,537 | | | 16,162 | | | 58,049 | | | 220,748 | | Prior periods | 33 | | | (352) | | | 612 | | | 293 | | Payments and customer credits issued | (144,231) | | | (16,028) | | | (56,479) | | | (216,738) | | Balance at December 31, 2020 | $ | 9,853 | | | $ | 3,279 | | | $ | 17,404 | | | $ | 30,536 | |
|
Schedule of Other Assets and Other Liabilities |
Contract assets and liabilities were as follows (in thousands): | | | | | | | | | | | | | December 31, | | 2020 | | 2019 | Contract assets(1) | $ | — | | | $ | 1,062 | | | | | | Contract liabilities: | | | | Current portion(2) | $ | 1,790 | | | $ | — | | Long-term portion(3) | 3,755 | | | 6,596 | | Total contract liabilities | $ | 5,545 | | | $ | 6,596 | |
____________________ (1) Presented in prepaid expenses and other current assets in the accompanying Consolidated Balance Sheets. (2) Presented in other current liabilities in the accompanying Consolidated Balance Sheets. (3) Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets.
|